Alvotech and STADA Launch Hukyndra (biosimilar, adalimumab) in the EU
Shots:
- Alvotech & STADA launched adalimumab biosimilar referencing Humira in 7 countries across the EU: Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania & Slovenia, following the initial launch in June 2022 in 9 other EU countries
- STADA gets Hukyndra autoinjectors & pre-filled syringes with drug products & drug substances manufactured in an EU facility in Reykjavik, Iceland & holds the marketing authorization rights in the EU, US & multiple other countries, supports adalimumab launches in national markets through tailored educational materials & patient-support programs
- Hukyndra was approved in the EU, Norway, Iceland, Lichtenstein, the UK & Switzerland; Canada as Simlandi & Australia as Ciptunec/ Ardalicip, now under review in multiple countries, incl. in the US
Ref: Globenewswire | Image: Alvotech
Related News:- Alvotech and STADA Launch Hukyndra (biosimilar, adalimumab) in Switzerland
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
